Inhibition of experimental acute pulmonary inflammation by pirfenidone (Q44505913)

3 December 2017

Inhibition of experimental acute pulmonary inflammation by pirfenidone (English)

1 reference

3 December 2017

0 references

Spond J

1

1 reference

3 December 2017

Case N

2

1 reference

3 December 2017

Chapman RW

3

1 reference

3 December 2017

Crawley Y

4

1 reference

3 December 2017

Egan RW

5

1 reference

3 December 2017

Fine J

6

1 reference

3 December 2017

Hey JA

7

1 reference

3 December 2017

Kreutner W

8

1 reference

3 December 2017

Kung T

9

1 reference

3 December 2017

Wang P

10

1 reference

3 December 2017

Minnicozzi M

11

1 reference

3 December 2017

1 January 2003

1 reference

Pulmonary Pharmacology & Therapeutics

3 December 2017

1 reference

3 December 2017

16

1 reference

3 December 2017

207-214

1 reference

3 December 2017

4

1 reference

Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis. Signs of eosinophil activation in the lung are related to impaired lung function

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Characterization of a murine model of allergic pulmonary inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Cytokines and therapy in COPD: a promising combination?

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Mediators of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Cytokines contribute to airway dysfunction in antigen-challenged guinea pigs: inhibition of airway hyperreactivity, pulmonary eosinophil accumulation, and tumor necrosis factor generation by pretreatment with an interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Molecular mechanisms of pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Remodeling in asthma and chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Consequences of long-term inflammation. Airway remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Airway remodeling and repair.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Pulmonary fibrosis: cytokines in the balance

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Glucocorticoid effects in an endotoxin-induced rat pulmonary inflammation model: differential effects on neutrophil influx, integrin expression, and inflammatory mediators

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Lung cytokines and ARDS: Roger S. Mitchell Lecture

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

TNF-alpha and IL-1 beta are not essential to the inflammatory response in LPS-induced airway disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Epithelium-fibroblast interactions in response to airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Characteristics of the Inflammatory response in bronchial lavage fluids from patients with status asthmaticus

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1094-5539%2803%2900026-9

7 January 2021

10.1016/S1094-5539(03)00026-9

Identifiers

DOI

1 reference

3 December 2017

1 reference